Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/ dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Cancer Biology and Therapy

Volumn 9, Issue 7, 2010, Pages 539-550

  Holland, Pamela M ^a   Miller, Robert ^a   Jones, Jon ^a   Douangpanya, Heather ^a   Piasecki, Julia ^a   Roudier, Martine ^a   Dougall, William C ^a  

^a AMGEN INC   (United States)

Author keywords

Apo2L TRAIL; Apoptosis; Bone metastases; Breast cancer; Dulanermin; Osteolysis; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTINEOPLASTIC AGENT; CALCIUM; CASPASE 3; CASPASE 7; DULANERMIN; FIREFLY LUCIFERASE; GREEN FLUORESCENT PROTEIN; GROWTH FACTOR; IMMUNOGLOBULIN G1; LENTIVIRUS VECTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B IMMUNOGLOBULIN G1 FC DOMAIN; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; BONE RADIOGRAPHY; BREAST ADENOCARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL STRAIN; CELL STRAIN MDA MB 231 BB; CELL STRAIN MDA MB 231 F11; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOLYSIS; TREATMENT DURATION; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

EID: 77953726348     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.7.11266     Document Type: Article

References (51)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-94.
2. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev 2005; 5:591-602.
3. Roodman GD. Mechanisms of bone metastasis. New Engl J Med 2004; 350:1655-64.
4. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treatment Rev 2008; 34:92-101. (Pubitemid 351181016)
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-42.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19. (Pubitemid 27199902)
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-602. (Pubitemid 28173173)
8. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139:4743-6. (Pubitemid 28487795)
9. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999; 140:3552-61.
10. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140:4451-8. (Pubitemid 30666108)
11. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Met 2008; 25:119-29.
12. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40:471-8. (Pubitemid 46070226)
13. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82. (Pubitemid 26091143)
14. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90. (Pubitemid 26175834)
15. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3.
16. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-97. (Pubitemid 27380146)
17. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NFkappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20.
18. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70. (Pubitemid 27441160)
19. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7. (Pubitemid 28319153)
20. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26:3621-30.
21. Herbst RS, Mendelson D, Ebbinghaus S, Gordon M, O'Dwyer P, Lieberman G, et al. A Phase 1 safety and pharmacokinetic study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006; 24:3013.
22. Soria JC, Smit EF, Khayat D, Besse B, Burton J, Yang X, et al. Phase 1b study of recombinant human (rh) Apo2L/TRAIL in combination with paclitaxel, carboplatin and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26.
23. Lee TJ, Lee JT, Park JW, Kwon TK. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. BBRC 2006; 351:1024-30.
24. Yoshida T, Zhang Y, Rosado LA, Zhang B. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 2009; 7:1835-44.
25. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275:23319-25. (Pubitemid 30646233)
26. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival? Breast Cancer Res 2005; 92:207-15.
27. Kapoor P, Suva LJ, Welch DR, Donahue HJ. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem 2008; 103:30-41.
28. Roudier M, Chaisson M, Branstetter D, Pretorius J, Tometsko M, Huang L, et al. Receptor activator of NFκB is expressed in human breast tumors and is functional on breast cancer cells. Breast Cancer Res 2006; 100:297.
29. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005; 7:444-54.
30. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62.
31. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics and safety. J Pharmacol Exp Ther 2001; 299:31-8. (Pubitemid 32905115)
32. Miller RE, Branstetter D, Armstrong A, Kennedy B, Jones J, Cowan L, et al. Receptor activator of NFkappaB ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 2007; 179:266-74. (Pubitemid 46986542)
33. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006; 25:541-9. (Pubitemid 46071863)
34. Dougall W, Chaisson M. Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases. Clinical Calcium 2006; 16:627-35.
35. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61:4432-6. (Pubitemid 32685771)
36. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008; 7:2160-9.
37. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003; 63:7883-90. (Pubitemid 37466723)
38. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NFkappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007; 282:31601-9. (Pubitemid 350044899)
39. De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008; 14:4713-8.
40. Izeradjene K, Douglas L, Delaney A, Houghton JA. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 2005; 24:2050-8. (Pubitemid 40516198)
41. Vaculova A, Hofmanova J, Soucek K, Kozubik A. Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Lett 2006; 580:6565-9. (Pubitemid 44827014)
42. Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, Holland PM. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 2007; 12:1465-78.
43. Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, et al. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res 2006; 66:5363-70. (Pubitemid 43844962)
44. Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, et al. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Molec Cancer Ther 2009; 8:2969-80.
45. Labrinidis A, Liapis V, Thai le M, Atkins GJ, Vincent C, Hay S, et al. Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood 2008; 111:5411-2.
46. Zauli G, Secchiero P. Role of TRAIL in osteoclastogenesis. Blood 2008; 111:5413.
47. Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008; 214:117-25.
48. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Med 2001; 7:383-5. (Pubitemid 32298514)
49. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14:6690-6.
50. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875-82.
51. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72:8463-71. (Pubitemid 28471781)